Trial Profile
Pharmacokinetics and Safety of Roledumab, a Fully Human Recombinant Monoclonal Anti-RhD Antibody, in RhD-negative Pregnant Woman Carrying an RhD-positive Foetus: a Phase IIb, Multicenter, Open-label Study
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Oct 2023
Price :
$35
*
At a glance
- Drugs Roledumab (Primary) ; Roledumab (Primary)
- Indications Haemolytic disease of newborn
- Focus Pharmacokinetics
- 05 Mar 2018 Status changed from active, no longer recruiting to completed.
- 01 Dec 2016 Planned End Date changed from 1 Oct 2017 to 1 Nov 2017.
- 01 Dec 2016 Planned primary completion date changed from 1 Oct 2017 to 1 Nov 2017.